Metronomic cyclophosphamide therapy in hormone-naive patients with non-metastatic biochemical recurrent prostate cancer: a phase II trial.

about

Metronomic cyclophosphamide therapy in hormone-naive patients with non-metastatic biochemical recurrent prostate cancer: a phase II trial.

Item

http://www.wikidata.org/entity/Q40657628

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Metronomic cyclophosphamide th ...... tate cancer: a phase II trial.

@en

type

Item

label

Metronomic cyclophosphamide th ...... tate cancer: a phase II trial.

@en

prefLabel

Metronomic cyclophosphamide th ...... tate cancer: a phase II trial.

@en

P1476

Metronomic cyclophosphamide th ...... tate cancer: a phase II trial.

@en

P2093

Christophe Borg

http://www.w3.org/2001/XMLSchema#string

E Curtit

http://www.w3.org/2001/XMLSchema#string

F Kleinclauss

http://www.w3.org/2001/XMLSchema#string

Guillaume Mouillet

http://www.w3.org/2001/XMLSchema#string

Olivier Adotevi

http://www.w3.org/2001/XMLSchema#string

Philippe Montcuquet

http://www.w3.org/2001/XMLSchema#string

Thierry Nguyen

http://www.w3.org/2001/XMLSchema#string

Tristan Maurina

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2010

Oral combination of cyclophosphamide, uracil plus tegafur and estramustine for hormone-refractory prostate cancer.

Salvage therapy with oral metronomic cyclophosphamide and methotrexate for castration-refractory metastatic adenocarcinoma of the prostate resistant to docetaxel.

Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients.

Natural history of progression after PSA elevation following radical prostatectomy.

Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.

Clinical outcome of patients with docetaxel-resistant hormone-refractory prostate cancer treated with second-line cyclophosphamide-based metronomic chemotherapy.

PSA progression following radical prostatectomy and radiation therapy: new standards in the new Millennium.

Intermittent androgen suppression for rising PSA level after radiotherapy.

VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide.

P2888

s12032-016-0806-0

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12032-016-0806-0

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Antoine Thiery-vuillemin

Xavier Pivot

Fabien Calcagno

P577

2016-07-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1046232551

http://www.w3.org/2001/XMLSchema#string

P698

27400698

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial